CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials

Abstract Menin inhibitors have entered clinical trials for histone lysine methyltransferase 2 A (KMT2A)-rearranged and nucleophosmin 1 (NPM1)-mutant acute leukemias and are demonstrating promising activity. CRISPR base editor screening previously predicted several MEN1 (menin) mutations that have ar...

Descripción completa

Detalles Bibliográficos

Autores principales:	Wallace Bourgeois, Hannah E. Rice, Daniela V. Wenge, Florian Perner, Hong Yue, Brandon D. Regalado, George Wan, Jan C. Schroeder, Alba Sommerschield, Charlie Hatton, Shivendra Singh, Sweta Singh, Shipra Bijpuria, Brian M. McKeever, William H. Miller, Jordan F. Safer, Sumaiya Iqbal, Jennifer A. Perry, Eric S. Fischer, John G. Doench, Gerard M. McGeehan, Jevon A. Cutler, Scott A. Armstrong
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2026-05-01
Colección:	Nature Communications
Acceso en línea:	https://doi.org/10.1038/s41467-026-72685-1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!